Merck is studying an investigational treatment through our Keynote Oncology Clinical Trials

Our Keynote Oncology Clinical Trials are studying a way to treat cancer through immunotherapy – an approach that may help the body’s immune system fight cancer. The investigational immunotherapy used in the Keynote Oncology Clinical Trials is called pembrolizumab (MK-3475).

Pembrolizumab has been FDA-approved for use in certain types of cancer.

Since many clinical trials involve new drugs or test drugs in new ways, there are risks associated with participation. It is important that patients understand these risks before agreeing to participate. The possible benefits and risks should be discussed with a doctor.


Immunotherapy is a type of therapy that may help the body’s immune system attack cancer cells. The investigational immunotherapy being studied is called pembrolizumab. Pembrolizumab blocks the interaction of PD-1 with another protein called PD-L1, which is sometimes found on tumor cells. Blocking this interaction may help the immune system recognize certain tumors and attack them.

Merck has investigational clinical trials under way or planned in more than 30 types of cancer. We are currently studying the following:

  • Bladder Cancer
  • Breast Cancer
  • Gastric Cancer
  • Head and Neck Cancer
  • Hematology
  • Melanoma
  • Lung Cancer
  • Ovarian Cancer
  • Pediatric
  • Colorectal Cancer
  • Esophageal Cancer
  • As well as other types of cancer

Select cancer type below: